Tetraphase Pharmaceuticals Inc. announced today that it has closed the second tranche of its $25 million Series A financing to support the advancement of several novel and potent antibiotic drug candidates. Tetraphase Pharmaceuticals was established in August 2006 to advance and commercialize the ground-breaking synthetic chemistry platform developed by internationally recognized chemist, Dr. Andrew Myers […]
Less
More
Inimex Pharmaceuticals, Inc. is pleased to announce the closing of a US $22 Million Series B venture financing. The funds will enable Inimex to conduct the first clinical trials of an Innate Defense Regulator (IDR) drug in patients and to evaluate IDR drugs in a broad range of disease models. IDRs are novel drugs that […]
AM-Pharma B.V., the biopharmaceutical company developing improved endogenous proteins and peptides to combat disease, today announced the signing of a EURO 7 million ($10.886 mm) financing agreement. Cash raised in this C round will allow the company to generate further Phase II efficacy and safety data for its two products; Recombinant human Alkaline Phosphatase and […]
Trius Therapeutics, Inc. today announced the close of a $30 million Series B financing to advance the clinical development of its best-in-class oxazolidinone antibacterial drug TR-701, now completing Phase I testing. Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by resistant pathogens. The company’s lead drug candidate, TR-701 […]
Novacta Biosystems, a UK-based developer of anti-infective therapeutics, has raised Gbp3.5 ($6.9 million). Proprietary products are focused on acne and skin infections, but they also do a lot of joint research work. This money was actually raised to target C. difficile infections: “C. difficile infections (CDIs) are a growing and serious problem and have, for […]
Cempra Pharmaceuticals Inc. has raised $10 million in Series B funding. Cempra is a biotechnology company founded to capture near-term value from market opportunities in antibiotics to meet urgent and continuing needs to treat drug-resistant bacteria in the hospital and community. The strategy is based on the pharmaceutical and biotechnology industry experience of Cempra’s founders […]
Paratek Pharmaceuticals, Inc. announced today that it has closed the first tranche of a $40 million private financing. Proceeds of the financing will be used primarily to advance Paratek’s lead programs to develop broad-spectrum antibiotics, including two antibiotics for the treatment of resistant bacterial infections such as those caused by Methicillin-Resistant Staphylococcus aureus (MRSA).
APT Pharmaceuticals, Inc. Closes New $22 Million Funding Round The company, which has received a total of $30 million in funding to date, will use the new funding to advance its development pipeline which includes Pulminiq, a Phase III drug for prevention of lung transplant rejection, a novel cardioprotectant and several other projects. They seem […]
OpGen is starting over, with $23.6 million in funding OpGen, founded in 2001, uses technology known as “optical mapping” to identify microorganisms by analyzing their DNA. The hospital microbial market is “still using 19th century technology. It’s the only one that hasn’t been automated,” Lennox said. “I think OpGen’s technology has the capability of really […]
AQUAPHARM Bio-Discovery, a leading Scottish marine biotechnology company, said yesterday it has completed a financing package worth pounds-1.5m and plans to move into the new European Centre for Marine Biotechnology Aquapharm collects samples of bacteria and fungi from the marine environment to build a microbial library and a natural products library. The library […]
MRSA
BioTechnology